文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Stott D J, Robertson J I, McLenachan J M, Ball S G

MRC Blood Pressure Unit, Western Infirmary, Glasgow, UK.

J Auton Pharmacol. 1989 Feb;9(1):45-51. doi: 10.1111/j.1474-8673.1989.tb00195.x.

The serotonergic type-2 (5HT2) antagonist ketanserin was given in a dose of 40 mg twice daily for 3 days to eight healthy subjects in a double-blind placebo controlled randomized crossover study. 2. The QTc interval was prolonged slightly but significantly (P less than 0.01) by a mean of 29 +/- 7 milliseconds after ketanserin compared to placebo. 3. Ketanserin reduced both mean arterial pressure and heart rate (P less than 0.05), by 5.7 +/- 1.8 mmHg and 3.5 +/- 1.5 beats minute-1 respectively, when compared to placebo. 4. There was a tendency (not statistically significant) for cardiac vagal outflow to be reduced after ketanserin (assessed by the heart rate responses to standing, deep breathing and the Valsalva manoeuvre). 5. In healthy man, ketanserin causes prolongation of the QTc interval and a reduction in heart rate. These changes do not appear to be due to enhanced cardiac parasympathetic activity.

在一项双盲、安慰剂对照、随机交叉研究中，给8名健康受试者每日两次服用剂量为40毫克的5-羟色胺能2型（5HT2）拮抗剂酮色林，持续3天。2. 与安慰剂相比，服用酮色林后，QTc间期平均延长29±7毫秒，延长幅度虽小但具有显著意义（P小于0.01）。3. 与安慰剂相比，酮色林可降低平均动脉压和心率（P小于0.05），平均动脉压降低5.7±1.8毫米汞柱，心率降低3.5±1.5次/分钟。4. 服用酮色林后，心脏迷走神经传出功能有降低趋势（通过站立、深呼吸和瓦尔萨尔瓦动作时的心率反应评估），但无统计学意义。5. 在健康男性中，酮色林可导致QTc间期延长和心率降低。这些变化似乎并非由心脏副交感神经活动增强所致。

Stott D J, Robertson J I, McLenachan J M, Ball S G

MRC Blood Pressure Unit, Western Infirmary, Glasgow, UK.

J Auton Pharmacol. 1989 Feb;9(1):45-51. doi: 10.1111/j.1474-8673.1989.tb00195.x.

The serotonergic type-2 (5HT2) antagonist ketanserin was given in a dose of 40 mg twice daily for 3 days to eight healthy subjects in a double-blind placebo controlled randomized crossover study. 2. The QTc interval was prolonged slightly but significantly (P less than 0.01) by a mean of 29 +/- 7 milliseconds after ketanserin compared to placebo. 3. Ketanserin reduced both mean arterial pressure and heart rate (P less than 0.05), by 5.7 +/- 1.8 mmHg and 3.5 +/- 1.5 beats minute-1 respectively, when compared to placebo. 4. There was a tendency (not statistically significant) for cardiac vagal outflow to be reduced after ketanserin (assessed by the heart rate responses to standing, deep breathing and the Valsalva manoeuvre). 5. In healthy man, ketanserin causes prolongation of the QTc interval and a reduction in heart rate. These changes do not appear to be due to enhanced cardiac parasympathetic activity.

在一项双盲、安慰剂对照、随机交叉研究中，给8名健康受试者每日两次服用剂量为40毫克的5-羟色胺能2型（5HT2）拮抗剂酮色林，持续3天。2. 与安慰剂相比，服用酮色林后，QTc间期平均延长29±7毫秒，延长幅度虽小但具有显著意义（P小于0.01）。3. 与安慰剂相比，酮色林可降低平均动脉压和心率（P小于0.05），平均动脉压降低5.7±1.8毫米汞柱，心率降低3.5±1.5次/分钟。4. 服用酮色林后，心脏迷走神经传出功能有降低趋势（通过站立、深呼吸和瓦尔萨尔瓦动作时的心率反应评估），但无统计学意义。5. 在健康男性中，酮色林可导致QTc间期延长和心率降低。这些变化似乎并非由心脏副交感神经活动增强所致。